C4 Therapeutics, Inc. (CCCC) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
CCCC Revenue Analysis (2018–2025)
As of March 1, 2026, C4 Therapeutics, Inc. (CCCC) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -581.6% year-over-year. The most recent quarter (Q4 2025) recorded $-24,931,000 in revenue, down 322.0% sequentially.
Looking at the longer-term picture, CCCC's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $45.8 million in 2021.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), CCCC has underperformed the peer group in terms of revenue growth. Compare CCCC vs REGN →
Peer Comparison
Compare CCCC's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CCCCCurrent | $0 | -581.6% | - | - | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $-115,222,000 | - |
| 2024 | $35.6M | +71.4% | $35.6M | 100.0% | $-119,614,000 | -336.1% |
| 2023 | $20.8M | -33.3% | $13.0M | 62.7% | $-139,031,000 | -669.8% |
| 2022 | $31.1M | -32.1% | $31.1M | 100.0% | $-129,534,000 | -416.6% |
| 2021 | $45.8M | +37.9% | $45.8M | 100.0% | $-82,134,000 | -179.4% |
| 2020 | $33.2M | +55.3% | $-45,245,000 | -136.3% | $-60,449,000 | -182.1% |
| 2019 | $21.4M | +10.4% | $21.4M | 100.0% | $-35,452,000 | -165.8% |
| 2018 | $19.4M | - | $-9,228,000 | -47.7% | $-16,389,000 | -84.6% |
See CCCC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCCC Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CCCC vs AGIO
See how CCCC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CCCC's revenue growth accelerating or slowing?
CCCC revenue declined -581.6% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is CCCC's long-term revenue growth rate?
C4 Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -581.6% is below this long-term average.
How is CCCC's revenue distributed by segment?
CCCC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.